If you liked this article you might like

Gilead, Pfizer, AbbVie Win From Lilly's Loss
Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis
Cramer: Retail Rally Shows the Perils of Being Too Negative
Regeneron Is Ready to Rally